Stem Cell Sources for Vascular Tissue Engineering and Regeneration

Bajpai, Vivek K.; Andreadis, Stelios T.

doi:10.1089/ten.teb.2011.0264

Cited by 82 publications

(62 citation statements)

References 300 publications

(241 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three major approaches have been taken to construct TEBVs, including using de-cellularized matrices [5–7], engineered cell-sheets [8, 9] and biodegradable scaffolds [10]. While many efforts are being made in the development of biomaterials and optimization of the microenvironment for vascular tissue formation, cell source remains one of the bottleneck problems [11]. Mature vascular cells isolated from the donor vessels may not be sufficient in number and suffer from limited proliferation potentials and the rapidly declining cell functions during in vitro expansion.…”

Section: Introductionmentioning

confidence: 99%

Engineering vascular tissue with functional smooth muscle cells derived from human iPS cells and nanofibrous scaffolds

et al. 2014

View full text Add to dashboard Cite

Tissue-engineered blood vessels (TEBVs) are promising in the replacement of diseased vascular tissues. However, it remains a great challenge to obtain a sufficient number of functional smooth muscle cells (SMCs) in a clinical setting to construct patient-specific TEBVs. In addition, it is critical to develop a scaffold to accommodate these cells and retain their functional phenotype for the regeneration of TEBVs. In this study, human induced pluripotent stem cells (iPSCs) were established from primary human aortic fibroblasts, and characterized with the pluripotency markers expression and cells’ capabilities to differentiate into all three germ layer cells. A highly efficient method was then developed to induce these human iPSCs into proliferative SMCs. After multiple times of expansion, the expanded SMCs retained the potential to be induced into the functional contractile phenotype of mature SMCs, which was characterized by the contractile response to carbachol treatment, up-regulation of specific collagen genes under transforming growth factor β1 treatment, and up-regulation of specific matrix metalloproteinase genes under cytokine stimulation. We also developed an advanced macroporous and nanofibrous (NF) poly(L-lactic acid) (PLLA) scaffold with suitable pore size and interpore connectivity to seed these human iPSC-derived SMCs and maintain their differentiated phenotype. Subcutaneous implantation of the SMC-scaffold construct in nude mice demonstrated vascular tissue formation, with robust collagenous matrix deposition inside the scaffold and the maintenance of differentiated SMC phenotype. Taken together, this study established an exciting approach towards the construction of patient-specific TEBVs. We established patient-specific human iPSCs, derived proliferative SMCs fore expansion, turned on their mature contractile SMC phenotype, and developed an advanced scaffold for these cells to regenerate vascular tissue in vivo.

show abstract

Section: Introductionmentioning

confidence: 99%

Engineering vascular tissue with functional smooth muscle cells derived from human iPS cells and nanofibrous scaffolds

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[17][18][19][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][57][58][59][60][61] Five of these articles specifically reviewed the use of stem cells for cardiovascular engineering. [57][58][59][60][61] Since these reviews were published, multiple articles have addressed the unique issues pertaining to the use of iPSCs, which may ultimately be the best solution to provide patient-specific cells, but will require improvements in efficiency of dedifferentiation, the elimination of the risk of teratoma formation, improved culture techniques, and novel methods for delivering the cells to the decellularized matrix.…”

Section: Strategies For Recellularizationmentioning

confidence: 99%

“…However, Chen et al attempted to replicate this method with contrary results. 38 Bajpai et al 57 and Jing et al 59 also have reviewed the potential and challenges of stem cells for repairing damaged heart tissue. Stem cells are unique in that a certain fraction proliferate and retain their ''stemness'' while others differentiate.…”

Section: Strategies For Recellularizationmentioning

confidence: 99%

Strategies and Processes to Decellularize and Recellularize Hearts to Generate Functional Organs and Reduce the Risk of Thrombosis

Momtahan

Sukavaneshvar²,

Roeder

et al. 2015

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

Heart failure is one of the leading causes of death in the United States. Current therapies, such as heart transplants and bioartificial hearts, are helpful, but not optimal. Decellularization of porcine whole hearts followed by recellularization with patient-specific human cells may provide the ultimate solution for patients with heart failure. Great progress has been made in the development of efficient processes for decellularization, and the design of automated bioreactors. Challenges remain in selecting and culturing cells, growing the cells on the decellularized scaffolds without contamination, characterizing the regenerated organs, and preventing thrombosis. Various strategies have been proposed to prevent thrombosis of blood-contacting devices, including reendothelization and the creation of nonfouling surfaces using surface modification technologies. This review discusses the progress and remaining challenges involved with recellularizing whole hearts, focusing on the prevention of thrombosis.

show abstract

“…23, 24 All three aspects are complementary and essential in the development of functional TEVGs with a hierarchy of organized structure. In addition, selection of an optimal animal model for the evaluation of TEVGs is crucial, which has been comprehensively reviewed elsewhere.…”

Section: Stem Cell Sources For Regenerating Tevgsmentioning

confidence: 99%

Fabrication of tissue-engineered vascular grafts with stem cells and stem cell-derived vascular cells

Wang

Sorek

et al. 2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction Cardiovascular disease is the leading cause of mortality worldwide. Current surgical treatments for cardiovascular disease include vascular bypass grafting and replacement with autologous blood vessels or synthetic vascular grafts. However, there is a call for better alternative biological grafts. Areas covered Tissue-engineered vascular grafts (TEVGs) are promising novel alternatives to replace diseased vessels. However, obtaining enough functional and clinically usable vascular cells for fabrication of TEVGs remains a major challenge. New findings in adult stem cells and recent advances in pluripotent stem cells have opened a new avenue for stem cell-based vascular engineering. In this review, recent advances on stem cell sourcing for TEVGs including the use of adult stem cells and pluripotent stem cells, and advantages, disadvantages, and possible future implementations of different types of stem cells will be discussed. In addition, current strategies used during the fabrication of TEVGs will be highlighted. Expert opinion The application of patient-specific TEVGs constructed with vascular cells derived from immune-compatible stem cells possesses huge clinical potential. Advances in lineage-specific differentiation approaches and innovative vascular engineering strategies will promote the vascular regeneration field from bench to bedside.

show abstract

Stem Cell Sources for Vascular Tissue Engineering and Regeneration

Cited by 82 publications

References 300 publications

Engineering vascular tissue with functional smooth muscle cells derived from human iPS cells and nanofibrous scaffolds

Engineering vascular tissue with functional smooth muscle cells derived from human iPS cells and nanofibrous scaffolds

Strategies and Processes to Decellularize and Recellularize Hearts to Generate Functional Organs and Reduce the Risk of Thrombosis

Fabrication of tissue-engineered vascular grafts with stem cells and stem cell-derived vascular cells

Contact Info

Product

Resources

About